BioPorto A/S
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIOPOR.CO research report →
About the company
BioPorto A/S is a Danish in-vitro diagnostics specialist, supplying biomarker tests, research tools, and antibodies to medical professionals and scientists worldwide, with operations across Europe, North America, and Asia. Among its offerings is the neutrophil gelatinase-associated lipocalin (NGAL) test, a precise quantitative particle-enhanced turbidimetric immunoassay designed for use on automated chemistry analyzers. The company further provides monoclonal antibodies essential for scientific, pharmaceutical, and clinical investigations.
- CEO
- Carsten Buhl
- IPO
- 2000
- Employees
- 48
- HQ
- Hellerup, DK
Price Chart
- Market Cap
- $547.08M
- P/E
- -6.06
- P/S
- 13.58
- P/B
- 8.68
- EV/EBITDA
- -6.01
- Div Yield
- 0.00%
- Gross Margin
- 75.44%
- Op Margin
- -213.70%
- Net Margin
- -203.83%
- ROE
- -166.86%
- ROIC
- -114.38%
- Revenue
- $40.29M · 11.16%
- Net Income
- $-82,117,000 · -20.33%
- EPS
- $-0.15 · 11.76%
- Op Income
- $-86,094,000
- FCF YoY
- 8.18%
- 52W High
- $1.53
- 52W Low
- $0.84
- 50D MA
- $1.15
- 200D MA
- $1.10
- Beta
- 1.38
- Avg Volume
- 490.09K
Get TickerSpark's AI analysis on BIOPOR.CO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our BIOPOR.CO coverage
Recent articles, reports, and earnings notes.
No research on BIOPOR.CO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BIOPOR.CO report →Similar companies
Peers in the same neighborhood.